세계의 철결핍성 빈혈 치료 시장 예측(-2028년) : 치료법별, 치료 영역별, 연령별, 최종 사용자별, 지역별 분석

According to Stratistics MRC, the Global Iron Deficiency Anemia (IDA) Therapy Market is accounted for $1.87 billion in 2022 and is expected to reach $2.36 billion by 2028 growing at a CAGR of 3.95% during the forecast period. Iron Deficiency Anemia (IDA) is a condition that occurs when there are not enough healthy red blood cells in the blood. Red blood cells, which aid in storing and transporting oxygen in the blood, are created using iron. RBCs provide oxygen to human tissues. Red blood cells contain iron, which is necessary for haemoglobin synthesis. An inadequate amount of haemoglobin may indicate that the body is not receiving enough oxygen. Foods rich in iron, such as fruits, meat, vegetables, and cereals, can be used to treat or prevent it. Consuming vitamin C can help prevent iron shortage.

According to the Global Nutrition Report, published in November 2021, it has been found that over half of Indian women aged between 15 - 49 years that is about 53% of the population are anemic.

Market Dynamics:

Driver:

Increased prevalence of iron deficiency anaemia

Iron Deficiency Anaemia (IDA) is a global health problem. It involves people of various ages and sexual orientations. However, teenage females are more susceptible to it. Increased iron need, monthly blood loss, illness, and worm infestation might be the causes. People who don't consume meat or other foods high in iron may be more susceptible to iron deficiency anaemia. Frequent blood donations and nutritional deficiencies are raising the demand for Iron Deficiency Anaemia (IDA) Therapies.

Restraint:

Lack of adequate testing

Anaemia may develop from a variety of different health issues. There aren't enough tests available to diagnose this condition. Anaemia tends to be neither properly assessed nor treated. It is commonly managed with iron supplements and recorded as a standalone diagnosis. The frequency and severity of its symptoms and indicators differ. It can cause heart failure or death if not adequately managed. These elements hinder the market demand.

Opportunity:

Growing incidence of cancer

Cancer patients are becoming more likely to have iron deficient anaemia. Lung and breast tumours have been shown to have the greatest anaemic frequency among solid tumours. Anaemia is caused by the aberrant blood cells that hematologic cancers like multiple myeloma, leukaemia, and lymphoma create. The immune system is weakened by these illnesses. Cancer treatments like chemotherapy and radiation worsen anaemia in cancer patients. These aspects create more prospects to the market.

Threat:

Side effects of iron supplements

Consuming iron-containing medications causes negative effects such as nausea, vomiting, stomach aches and constipation and issues with appetite. These medications can also cause overdose symptoms such fatigue, weakness, shallow or rapid breathing, blue skin, convulsions, pale skin, or pale fingernails. All of these adverse impacts are hampering the market expansion.

COVID-19 Impact:

The COVID-19 pandemic had a tremendous influence on the healthcare systems, with serious ramifications for both COVID-19-infected patients and non-infected patients, leading to the cancellation of treatment and procedures to manage and reserve resources. The prevalence of anaemia in COVID-19 patients resulted in a rise in the need for iron therapy and other anaemia-related treatments.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to have a lucrative growth. Children frequently struggle with an iron shortage. It can take several forms, ranging from a minor deficit to iron deficiency anaemia. A child's growth and development might be impacted by untreated iron deficiency. Children's iron deficiencies are usually caused by inadequate nutrition, fast development, and low birth weight. Raising diagnosis of haemoglobin and hematocrit are driving the segment's demand.

The oral iron therapy segment is expected to have the highest CAGR during the forecast period

The oral iron therapy segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its high iron balance restoring capacity. To replenish iron reserves and normalise ferritin levels, oral iron treatment must be used for at least three to six months. By raising the body's iron and haemoglobin levels, it alleviates the patient's symptoms. Different levels of elemental iron are included in oral iron supplements.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to its developed healthcare system. The demand for iron deficiency anaemia treatments is increasing due to the region's developed healthcare infrastructure and the presence of significant market competitors. Additionally, expanding consumer awareness of women's health issues and technical improvements are propelling market expansion in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the increasing population and government initiatives. This region has huge population of women. The market demand in this area is being driven by rising healthcare costs, government initiatives to support the healthcare sector, and growing demand for IDA treatment.

Key players in the market:

Some of the key players profiled in the Iron Deficiency Anemia (IDA) Therapy Market include: Vifor Pharma Ltd, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, Novartis AG, Mylan N.V., Lupin, Zydus Cadila, GlaxoSmithKline plc, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd, Shield Therapeutics, Pharmacosmos A/S, AMAG Pharmaceuticals, Akebia Therapeutics, Inc, AbbVie Inc., Hikma Pharmaceuticals plc, Alkem Laboratiories, Advanz Pharmaceutical and Rockwell Medical, Inc.

Key Developments:

In February 2023, Rockwell Medical, Inc. announced that the Company signed a three-year product purchase agreement with Concerto Renal Services ("Concerto"), the largest provider of dialysis in skilled nursing facilities in the United States. Under the terms of the agreement, Rockwell Medical will be the primary supplier of liquid and dry acid and bicarbonate concentrates to Concerto through a three-year commitment that includes supply and purchasing minimums.

In September 2022, Alkem Laboratories announced that its off-the-shelf cell therapy product, StemOne has received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. The product, launched by Alkem Laboratories in collaboration with Stempeutics, is for the treatment of Knee Osteoarthritis, a degenerative disease of the joint.

In March 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of its first generic version of Revlimid®1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.

Therapies Covered:

• Parenteral Iron Therapy
• Oral Iron Therapy
• Red Blood Cell Transfusion Therapy
• Other Therapies

Therapy Areas Covered:

• Congestive Heart Failure (CHF)
• Renal, Obstetrics & Gynaecology
• Oncology
• Inflammatory Bowel Disease
• Other Therapy Areas

Age Covered:

• Geriatric
• Adults
• Pediatric

End Users Covered:

• Clinics
• Hospitals
• Home Healthcare

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy

• 5.1 Introduction
• 5.2 Parenteral Iron Therapy
• 5.3 Oral Iron Therapy
• 5.4 Red Blood Cell Transfusion Therapy
• 5.5 Other Therapies

6 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy Area

• 6.1 Introduction
• 6.2 Congestive Heart Failure (CHF)
• 6.3 Renal, Obstetrics & Gynaecology
• 6.4 Oncology
• 6.5 Inflammatory Bowel Disease
• 6.6 Other Therapy Areas

7 Global Iron Deficiency Anemia (IDA) Therapy Market, By Age

• 7.1 Introduction
• 7.2 Geriatric
• 7.3 Adults
• 7.4 Pediatric

8 Global Iron Deficiency Anemia (IDA) Therapy Market, By End User

• 8.1 Introduction
• 8.2 Clinics
• 8.3 Hospitals
• 8.4 Home Healthcare

9 Global Iron Deficiency Anemia (IDA) Therapy Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Vifor Pharma Ltd
• 11.2 Teva Pharmaceutical Industries Ltd
• 11.3 Sanofi
• 11.4 Pfizer Inc
• 11.5 Novartis AG
• 11.6 Mylan N.V.
• 11.7 Lupin
• 11.8 Zydus Cadila
• 11.9 GlaxoSmithKline plc
• 11.10 Fresenius SE & Co. KGaA
• 11.11 F. Hoffmann-La Roche Ltd
• 11.12 Shield Therapeutics
• 11.13 Pharmacosmos A/S
• 11.14 AMAG Pharmaceuticals
• 11.15 Akebia Therapeutics, Inc
• 11.16 AbbVie Inc.
• 11.17 Hikma Pharmaceuticals plc
• 11.18 Alkem Laboratiories
• 11.19 Advanz Pharmaceutical
• 11.20 Rockwell Medical, Inc